Category - Developments

Developments

Senzime launches new EMG sensor for anesthesia monitoring

Senzime (STO: SEZI; OTCQX: SNZZF) has announced the launch of its TetraSens electromyography (EMG) sensor for use with the TetraGraph Train-of-Four monitoring system for anesthesia monitoring. According to Senzime, the...

June 1, 2026

Developments

Sunshine announces Canadian approval of generic Rivaroxaban

Sunshine Biopharma (NASDAQ: SBFM) has announced the Canadian approval of Rivaroxaban—its generic equivalent of the brand Xarelto—in tablets of 2.5 mg, 10 mg, 15 mg, and 20 mg for the treatment and prevention of deep...

June 1, 2026

Developments

Cercare and Siemens announce global collaboration on CBCT-P guided stroke treatment

Closely held Cercare Medical and Siemens Healthineers (FSE: SHL) have announced a global collaboration to accelerate the adoption of Cone-Beam CT Perfusion (CBCT-P) in acute stroke care, leveraging its capability to...

May 28, 2026

Developments

BioXcel presents positive data for BXCL501 in bipolar or schizophrenia at ASCP

BioXcel Therapeutics (NASDAQ: BTAI) has announced new positive Phase 3 SERENITY At-Home data for BXCL501 in agitation associated with bipolar disorders or schizophrenia, to be presented this week at the 2026 American...

May 28, 2026

Developments

Conexeu launches preclinical program for B.R.E.A.S.T. with WFIRM

Conexeu Sciences (NASDAQ: CNXU) has initiated a preclinical development program for B.R.E.A.S.T. (BIO-REGENERATIVE ERGONOMICALLY ARCHITECTED SMART TISSUE), its recently unveiled 3D-printed bioregenerative breast matrix...

May 28, 2026

Developments

The iMRI revolution gets another boost from AiM’s collaboration with Siemens to advance robotic neurosurgery

Closely held AiM Medical Robotics has announced a collaboration agreement with Siemens Healthineers (FSE: SHL) for the implementation of an interface enabling AiM’s robotic platform to operate with MRI systems...

May 27, 2026

Developments

Kura reports compelling data from trial of FTI in solid tumors

Kura Oncology (NASDAQ: KURA) has reported compelling first-in-human data from the FIT-001 clinical trial of its next-generation farnesyl transferase inhibitor (FTI) darlifarnib in combination with adagrasib in heavily...

May 26, 2026

Developments

Percheron secures pINN from WHO for investigational cancer therapy

Percheron Therapeutics (ASX: PER; OTC: PERCF) has secured a potential international nonproprietary name (pINN) from the World Health Organization (WHO) for its investigational cancer therapy HMBD-002. According to...

May 26, 2026

Developments

Assembly broadens program into cholestatic liver diseases

Assembly Biosciences (NASDAQ: ASMB) has announced plans to expand the clinical development of ABI-6250, its oral entry inhibitor candidate for chronic hepatitis delta virus (HDV) infection, into primary biliary...

May 22, 2026

Developments

RCH doses first patient in Arch Phase 2 trial of LSALT peptide in CS-AKI

Arch Biopartners (TSXV: ARCH; OTCQB: ACHFF) has announced that Royal Columbian Hospital (RCH) has dosed its first patient in the ongoing Phase 2 trial evaluating LSALT peptide as a new drug to prevent acute kidney...

May 22, 2026

Category - Developments

Subscribe